



POSTER PRESENTATION

Open Access

# Toll like receptor 2 is overexpressed in FMF patients during attacks and inhibited by colchicine treatment

H Ben-David<sup>1\*</sup>, V Hornung<sup>2</sup>, T Ebert<sup>2</sup>, A Livneh<sup>1,3,4</sup>, I Ben-Zvi<sup>1,3,4</sup>

From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases Dresden, Germany. 30 September - 3 October 2015

## Background

FMF is a systemic auto-inflammatory disorder, characterized by recurrent episodes of fever and serosal inflammation. The *MEF* gene, which is associated with FMF, encodes for the protein pyrin. FMF associated mutations, interrupt with pyrin normal function, leading to activation of the innate immune system and overexpression of IL-1 $\beta$ , and consequently to a systemic inflammatory response. Toll-like receptors (TLRs) play an essential role in the innate immune responses, by recognition of pathogen-associated molecular patterns and endogenous peptides. TLRs trigger a cascade of signaling events, leading to cytokine production. TLR2 is implicated in several inflammatory conditions, but its role in the pathogenesis of FMF is not completely clear.

## Objectives

To study the role of TLR2 in the inflammatory process of FMF.

## Materials and methods

We tested TLR2 naïve expression on monocytes of FMF attack-free patients (n=20) by FACS. We further tested the effect of sera from FMF patients in acute attack (n=6) on TLR2 expression by monocytes of healthy controls. The role of TLR2 was studied in respect to *MEFV* mutation, performed in THP-1 cells. TLR2 downstream signaling was studied by ELISA to measure IL-1 $\beta$  secretion, or by Western-blot to measure NF- $\kappa$ B.

## Results

FMF attack-free patients have increased CD14<sup>+</sup>TLR2<sup>+</sup> cell-count, as compared to healthy donors. High dose of colchicine treatment ( $\geq 2$ mg/d) inhibited this increased expression of TLR2 in FMF patients. Colchicine *in vitro* also inhibited the levels of TLR2 expression on THP-1 cells. Sera from FMF patients in acute attack induced TLR2 expression by both monocytes of healthy donors and THP-1 cells, and IL-1 $\beta$  secretion in healthy monocytes, and colchicine inhibited this induction. Furthermore, TLR2 agonist (Pam2CSK4) increased the secretion of IL-1 $\beta$  by PBMCs of healthy donors, and this activation was inhibited by colchicine. In *MEFV*-mutated THP-1 cells, TLR2 expression was spontaneously up-regulated by 3.8 folds, while TLR4 expression was elevated by 2 folds as compared to wild-type. Wild-type THP-1 cells presented elevated NF- $\kappa$ B expression when cultured with Pam2CSK4, whereas colchicine treatment abolished this expression. *MEFV*-mutated THP-1 cells expressed elevated levels of NF- $\kappa$ B, as compared to their wild-type counterparts.

## Conclusion

TLR2 activation is up-regulated in monocytes of FMF patients, and colchicine inhibits this up-regulation *in-vitro* and *in-vivo*. Elevated expression of TLR2 promotes IL-1 $\beta$  production, and thus contribute to the uncontrolled inflammation manifested in FMF.

## Authors' details

<sup>1</sup>Sheba Medical Centre tel-Hashomer, Heller Institute of Medical Research, Ramat-Gan, Israel. <sup>2</sup>Bonn University, Institute for Molecular Medicine, Bonn, Germany. <sup>3</sup>Sheba Medical Centre Tel-Hashomer, Rheumatology unit & Department of Internal Medicine F, Ramat Gan, Israel. <sup>4</sup>Tel-Aviv University, Sackler Faculty of Medicine, Tel-Aviv, Israel.

<sup>1</sup>Sheba Medical Centre tel-Hashomer, Heller Institute of Medical Research, Ramat-Gan, Israel

Full list of author information is available at the end of the article

Published: 28 September 2015

doi:10.1186/1546-0096-13-S1-P74

**Cite this article as:** Ben-David *et al.*: Toll like receptor 2 is overexpressed in FMF patients during attacks and inhibited by colchicine treatment. *Pediatric Rheumatology* 2015 **13**(Suppl 1):P74.

**Submit your next manuscript to BioMed Central  
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at  
[www.biomedcentral.com/submit](http://www.biomedcentral.com/submit)

